Key takeaways
- IGF-1 is the practical marker of growth hormone activity because GH is pulsatile and a single measurement of it is meaningless.
- It is also a nutrition marker - hepatic production requires adequate energy, protein and liver function, so under-eating and poor sleep suppress it.
- A raw value cannot be interpreted without age; the same number is unremarkable at 35 and near the top of the range at 65.
- A persistently high value warrants evaluation rather than reassurance, since IGF-1 is the screening test for acromegaly.
- The same signal supports lean mass and supports proliferation, so the target is the middle of the age-appropriate range, not the top.
IGF-1 is treated as a simple readout: high is anabolic and youthful, low is decline. It is more interesting than that, and considerably less obedient. The same number carries at least three different meanings depending on age, nutritional state and what else is on the panel, and the longevity literature and the body-composition literature want it to move in opposite directions. Reading it well is mostly a matter of knowing which question you are asking of it.
What it is and where it comes from
Insulin-like growth factor 1 is a peptide hormone produced mainly by the liver in response to growth hormone signalling, with additional local production in muscle and other tissues. It mediates most of what growth hormone is credited with: tissue growth, protein synthesis, and effects on body composition and repair.
In circulation almost none of it is free. The great majority is bound to IGF binding proteins, principally IGFBP-3, in a complex that extends its half-life from minutes to hours. That binding is what makes the measurement usable — it buffers the hormone into a stable pool rather than a series of spikes.
Why nobody measures growth hormone directly
Growth hormone is secreted in pulses, mostly during slow-wave sleep, with low or undetectable levels between them. A single random measurement is therefore close to meaningless: draw during a pulse and it looks high, draw between pulses and it looks absent, and neither result describes the day. Formal assessment requires dynamic stimulation testing, which is neither cheap nor routine. Hormone pulsatility covers why several axes have this problem.
IGF-1 solves it by integration. Because it is produced continuously in response to accumulated GH exposure and is buffered by its binding proteins, one sample gives a stable estimate of average GH activity over days. It is a surrogate, and a good one — provided you remember it is a surrogate for GH signalling, not for GH secretion. Those come apart when the liver is not in a position to respond.
The part usually missed: it is also a nutrition marker
Hepatic IGF-1 production requires adequate energy and protein and functional liver tissue. Under-eating suppresses it. So does a sustained energy deficit, a low protein intake, liver disease, poorly controlled hypothyroidism, and systemic inflammation.
The clinical consequence is direct: a low IGF-1 in someone dieting hard, training heavily and sleeping badly is not evidence of a pituitary problem. It is the expected result. Interpreting that number as growth hormone deficiency, and acting on it, is the most common error made with this test. Correct the inputs first and re-measure — the value frequently normalises without anything else being done.
Age-adjusted, always
IGF-1 declines steadily across adult life, so a raw value with no age attached cannot be interpreted at all (Brabant et al., Pituitary 2007). Broad age-referenced ranges:
- Age 20-30: 200-400 ng/mL
- Age 30-40: 180-300 ng/mL
- Age 40-50: 140-260 ng/mL
- Age 50-60: 120-220 ng/mL
- Age 60-70: 100-200 ng/mL
A value of 180 is unremarkable at 35 and near the top of the range at 65. Two further cautions: assays differ enough between laboratories that serial tracking should stay with one, and the result should be reported as a standard deviation score against the age reference wherever possible, because that is the form clinicians actually act on.
Reading a low result
Work through the differential in order of likelihood, not order of interest.
| Cause | What points to it |
|---|---|
| Energy deficit or low protein intake | Dieting, high training load, weight falling |
| Chronic poor sleep | Short or fragmented sleep; untreated apnoea |
| Hypothyroidism | Thyroid panel abnormal; IGF-1 often corrects on treatment |
| Liver disease | Abnormal liver enzymes or synthetic function |
| Systemic inflammation | Raised hs-CRP; treat the driver |
| True GH deficiency | Rare in adults; pituitary history, other axes affected; requires stimulation testing |
The last row is the least likely and the one people jump to. Adult growth hormone deficiency is a defined diagnosis with a defined workup, usually in the context of pituitary disease, surgery, radiotherapy or head injury — not something inferred from one low number in a healthy adult.
Reading a high result
A value well above the age reference has a short differential: laboratory error, exogenous growth hormone or secretagogue use, and — rarely but importantly — acromegaly from a pituitary adenoma. IGF-1 is the recommended screening test for acromegaly precisely because it integrates GH exposure, and a persistently raised value warrants proper endocrine evaluation rather than reassurance (Katznelson et al., J Clin Endocrinol Metab 2014). The clinical picture — hand and foot size change, jaw and facial change, headaches, new glucose intolerance, sleep apnoea — matters as much as the number.
The trade-off nobody resolves
Here is where the two literatures collide. Higher IGF-1 supports lean mass, recovery and bone, and low IGF-1 in older adults is associated with frailty, reduced muscle and worse functional outcomes. That argues for keeping it in the healthy part of the age range.
At the same time, IGF-1 is a proliferative signal. Large prospective analyses find higher circulating IGF-1 associated with increased risk of certain cancers, particularly breast and prostate (Murphy et al., cohort analysis of IGF-1 and cancer risk). And the relationship with mortality is not monotonic: meta-analysis suggests risk rises at both ends of the distribution rather than falling steadily as IGF-1 climbs (Burgers et al., J Clin Endocrinol Metab 2011).
This is the same tension that runs through the growth-versus-maintenance debate more generally — the trade-off examined in AMPK versus mTOR and in the longevity diet. There is no resolved optimum. The defensible position is the middle of the age-appropriate range rather than the top of it, and a strong scepticism toward anything whose stated purpose is to drive the number up.
What actually moves it
The levers are unglamorous and they are the same ones that move most things.
- Deep sleep. The largest natural lever, because most GH secretion occurs in slow-wave sleep — see sleep architecture and hormones. Untreated sleep apnoea suppresses it directly.
- Adequate energy. Chronic under-eating lowers it, and this is a feature of the system rather than a malfunction.
- Adequate protein, since hepatic synthesis requires substrate.
- Resistance training, which supports the tissue-level signalling that matters more than the circulating number.
- Treating hypothyroidism, liver disease or inflammation where present.
Growth hormone therapy is reserved for confirmed deficiency diagnosed on formal testing, which is a narrow and specific clinical situation. It is not an optimisation tool, and IGF-1 is not a score to maximise.
The clinical pearl: before treating a low IGF-1 as a hormone problem, check whether it is a food-and-sleep problem. In a lean, hard-training, calorie-restricted adult it usually is, and it usually corrects on its own once those inputs change. Re-testing after eight to twelve weeks of adequate intake and sleep resolves more of these than any intervention.
Bottom line
IGF-1 is the practical marker of growth hormone activity because GH itself is too pulsatile to measure directly. It must be read against age, from a consistent laboratory, and with the understanding that it also reports energy, protein, sleep, thyroid and liver status — which is why a low value is far more often nutritional than pituitary. High values warrant evaluation rather than celebration. And because the same signal supports lean mass and supports proliferation, the target is the middle of the age-appropriate range, reached through sleep, food and training rather than pushed there pharmacologically.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
